BSC® Knowledge Base
In-Depth Insights Gathered Over Four Decades.
August 28, 2026 at 6:54:00 PM
E9(R1) Addendum: Estimands & Sensitivity Analysis in Medical Device Trials
Trial Design & Methodology
September 1, 2026 at 1:25:00 PM
Beyond the Data: The Strategic Role of Clinical Outcome Assessments in Regulatory Success
Trial Design & Methodology
September 1, 2026 at 1:28:00 PM
Randomization and Kit Lists: What They Are and Why They Matter
Trial Design & Methodology
September 1, 2026 at 1:34:00 PM
Overview of Building 66 at the FDA White Oak Campus
Industry Landscape
September 1, 2026 at 1:35:00 PM
Multiple Endpoints in Clinical Trials: Why Medical Device Manufacturers Can't Afford to Ignore Multiplicity
Trial Design & Methodology
September 1, 2026 at 1:35:00 PM
FDA Q-Submission Program 2025: What Medical Device Innovators Need to Know
FDA Regulatory Strategy
September 1, 2026 at 1:36:00 PM
In Silico Trials: Transforming Medical Device Development Through Digital Innovation
FDA Regulatory Strategy
September 1, 2026 at 1:42:00 PM
E9 Statistical Principles for Clinical Trials: The Foundation of Regulatory Success
Trial Design & Methodology
September 1, 2026 at 1:56:00 PM
Understanding the Content of Premarket Submissions for Device Software Functions
FDA Regulatory Strategy
September 1, 2026 at 1:58:00 PM
Non-Inferiority (NI) Trial Design and Strategy
Trial Design & Methodology
September 1, 2026 at 1:59:00 PM
What is MDR? Understanding Medical Device Regulation Compliance
FDA Regulatory Strategy
September 1, 2026 at 2:01:00 PM
The Strategic Edge in FDA Submissions: Applying "Least Burdensome"
FDA Regulatory Strategy
September 1, 2026 at 2:03:00 PM
The Critical Role of Radiographic Data in Medical Device Clinical Trials
Trial Design & Methodology
September 1, 2026 at 2:05:00 PM
FDA Breakthrough Device Designation: Accelerating Innovation in Medical Technology
FDA Regulatory Strategy
September 1, 2026 at 2:06:00 PM
Clinical Data Presentations for Orthopedic Device Applications
FDA Regulatory Strategy
September 1, 2026 at 2:08:00 PM
Primary vs Secondary vs Exploratory: Building the Right Endpoint Hierarchy for FDA Success
Trial Design & Methodology
September 1, 2026 at 2:09:00 PM
The 10 Largest Clinical Research Organizations (CROs)
Industry Landscape
September 1, 2026 at 2:15:00 PM
CROs & Venture Capital: Accelerating Biotech Innovation
Industry Landscape
WHAT CLIENTS SAY
“They listen the first time. I’ve never had to go back and respell out what I needed."
”They work to understand the problem and leverage the information that is already there.”
Former FDA Regulator
WHAT CLIENTS SAY
"Battle ground tested."
"There is nothing that David and team haven’t seen over the years – the good, bad, and ugly.”
Vice President, Clinical Operations
WHAT CLIENTS SAY
"Get stuff done when you have to do something no one else has done before."
"They aren’t afraid to tackle difficult scenarios in compressed timelines."
CEO, Medical Device Company
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.
Regulatory-first biostatistics
Support built specifically for FDA-facing programs, from early feasibility through submission and post-market requirements.
Direct communication, faster turn around
Our biostatisticians write the SAP and run the analysis. One person owns both — no separate programmer, no project manager in between.
Versatile Solutions
Engage us for a focused analysis or a full submission, We size the work to the problem.
Proven FDA Experience
Hands-On Experience with FDA Pathways, statistical reviews, and regular interactions, reducing risk and rework.